Thanks for sharing this valuable article from the press. This is relevant in respect to what we had talked about in class, namely incentives offered by Pharma to physicians a.k.a. Pharma-Physician or Doctor-Pharmaceutical relationship.
However, often, there is so much negative press on the subject that we rarely stop to think about the flip side. While the headlines focus on payments to physicians who act as consultants for pharmaceutical companies, the untold story is that there are tens of thousands of medical practices that recognize the fundamental value pharma reps bring to providers and patients. Tell me about it….
Let’s think a bit more about this in reference to Pakistan…But, please note that senators and members of the House of Representatives in the US too have been (or should I say had been) receiving big bucks from Pharma…I guess it is just a case of coming up with legislation or …people are people and pharma reps are just the same and can be overzealous at times…for bonuses and also for company profitability.
The Sunshine Act (USA)
Introduced as part of the Affordable Care Act, the Sunshine Act intends to bring transparency to financial relationships between medical device and drug manufacturers and physicians to decrease the potential for conflict of interest in selecting appropriate treatments for patients. Beginning in July 2013, drug, device, biological product, and medical supply manufacturers will start reporting to CMS information on compensation, gifts, and other “transfers of value” paid to physicians.
So guess what there is a solution, i.e. need for legislation.
Updated 2014-04-19 12:34:10
ISLAMABAD: The Drug Regulatory Authority of Pakistan (DRAP) has asked the pharmaceutical companies to provide details of the doctors and hospitals who have been receiving financial and other benefits from them.
There is a general perception that pharmaceutical companies give financial benefits to the doctors and hospitals who in return prescribe medicines of the companies. However, there are a number of doctors who do not get benefits.
A press release issued on Friday says that Awareness and Prevention Division of NAB has advised DRAP to instruct all pharmaceutical companies to share their data regarding expenses incurred on marketing of drugs and incentive they give to doctors on their website.
The directive has been issued under the relevant law of Drug Act 1976.
The data should contain complete list of doctors/consultants, who were invited for conferences and given financial benefits and other facilities (gifts, appliances, excursion, foreign tours, etc.), says the press release.
An official of Ministry of National Health Services requesting not to be identified said that on Friday letters signed by Deputy Director General Pharmacovigilance Abdul Rasheed have been sent to the three representative bodies of pharmaceutical companies.
“Letters have been sent to Pakistan Pharmaceutical Manufacturers Association (PPMA), Pakistan Pharmaceutical Importer Association (PPIA) and Pharma Bureau with instructions to provide details within seven days,” he said.
“NAB has taken a positive step but it should implement it in letter and sprit,” he said.
State Minister for National Health Services Saira Afzal Tarar while talking to Dawn said that two months back she instructed DRAP to upload information regarding companies on the website.
However she said that she was not aware of the recent development.